The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.
The fallout from the F.D.A.’s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized.